Newsroom

Sorted by: Latest

-

Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-

Esco Aster firma un contrato de fabricación de cGMP clínicas de exosomas con Shine-On Biomedical para una novedosa plataforma de administración de fármacos de exosomas dirigidos a HLA-G, la primera de su clase

SINGAPUR--(BUSINESS WIRE)--Esco Aster, una organización de investigación, desarrollo y fabricación por contrato (CRDMO) de células y derivados verticalmente integrada con sede en JTC LaunchPad (Singapur), anunció apoyo de fabricación de química, fabricación y controles para el programa de exosomas dirigidos a HLA-G de Shine-On Biomedical. Shine-On Biomedical patrocinó a Esco Aster en 2023 en servicios de buenas prácticas de fabricación actuales (cGMP), comenzando con el desarrollo de exosomas d...
-

Esco Aster firma um contrato de fabricação clínica de exossomos, em conformidade com as Boas Práticas de Fabricação (cGMP), com a Shine-On Biomedical para uma plataforma inovadora e inédita de administração de fármacos por exossomos direcionados...

SINGAPURA--(BUSINESS WIRE)--  Esco Aster firma um contrato de fabricação clínica de exossomos, em conformidade com as Boas Práticas de Fabricação (cGMP), com a Shine-On Biomedical para uma plataforma inovadora e inédita de administração de fármacos por exossomos direcionados ao HLA-G A Esco Aster, uma CRDMO verticalmente integrada de células e derivados com sede no JTC LaunchPad Singapore, anunciou o suporte à produção CMC para o programa de exossomos voltados para o HLA-G, desenvolvido pela Sh...
-

Dongfeng Motor Holds Global Partnership Summit to Accelerate New Energy Expansion

SHIYAN, China--(BUSINESS WIRE)--On November 19, the 2026 Overseas Commercial Vehicle Partnership Summit was held in Shiyan, Hubei Province. During the Summit, Dongfeng G Series high-end truck brand has offically launched for overseas markets. Integrating top-tier global supply chains and having undergone rigorous testing, the G Series offers outstanding durability and cost efficiency. With leading technologies benchmarking against world-class brands, it aims to provide efficient transportation...
-

Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-

Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-

Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-

Sherritt and Pala Announce Board Renewal and Collaboration Agreement

TORONTO--(BUSINESS WIRE)--Sherritt International Corporation (“Sherritt” or the “Corporation”) (TSX:S) today announced that it has entered into a collaboration agreement (the “Agreement”) with Pala Assets Holdings Limited (“Pala”). Under the terms of the Agreement, Pala has withdrawn its requisition for a special meeting of shareholders, agreed to customary standstill and voting covenants, and Sherritt has made certain board and committee changes that will support the leadership transition and...
-

Resumen: Los clientes de Volante Technologies superan con éxito los plazos reglamentarios críticos para los pagos transfronterizos instantáneos SEPA de la UE y SWIFT globales

LONDRES--(BUSINESS WIRE)--Volante Technologies, líder mundial en pagos como servicio (PaaS), acaba de anunciar que ha puesto a sus clientes al día para que cumplan con la última normativa reglamento de pagos instantáneos (IPR, por sus siglas en inglés) de la SEPA y el mandato SWIFT SRG 2025, que entraron en vigor el 9 de octubre y el 22 de noviembre de 2025, respectivamente. Este anuncio llega después de la importante actualización de FedISO en julio, que migró billones de dólares en pagos al n...
-

Esco Aster unterzeichnet klinischen cGMP-Fertigungsvertrag für Exosomen mit Shine-On Biomedical für eine neuartige, First-in-Class-HLA-G-zielgerichtete Exosomen-Wirkstoffplattform

SINGAPUR--(BUSINESS WIRE)--Esco Aster, eine vertikal integrierte Auftragsfertigungsorganisation (CRDMO) für Zellen und Derivate mit Sitz im JTC LaunchPad Singapur, gab ihre Unterstützung bei der CMC-Fertigung für das HLA-G-zielgerichtete Exosomen-Programm von Shine-On Biomedical bekannt. Shine-On Biomedical beauftragte Esco Aster bereits im Jahr 2023 mit cGMP-Dienstleistungen, beginnend mit der Entwicklung hochreiner Exosomen unter Verwendung der Zelllinienplattform von Esco Aster. Die technisc...